JP2010507594A - 完全ヒト抗ｖｅｇｆ抗体および使用方法 - Google Patents

完全ヒト抗ｖｅｇｆ抗体および使用方法 Download PDF

Info

Publication number
JP2010507594A
JP2010507594A JP2009533598A JP2009533598A JP2010507594A JP 2010507594 A JP2010507594 A JP 2010507594A JP 2009533598 A JP2009533598 A JP 2009533598A JP 2009533598 A JP2009533598 A JP 2009533598A JP 2010507594 A JP2010507594 A JP 2010507594A
Authority
JP
Japan
Prior art keywords
antibody
seq
vegf
xpa
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009533598A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010507594A5 (enExample
Inventor
スマント・ラマチャンドラ
ウォルター・ロバート・ビショップ
リンダ・マサト
チャオ・バイ・フアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2010507594A publication Critical patent/JP2010507594A/ja
Publication of JP2010507594A5 publication Critical patent/JP2010507594A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2009533598A 2006-10-20 2007-10-22 完全ヒト抗ｖｅｇｆ抗体および使用方法 Pending JP2010507594A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85326006P 2006-10-20 2006-10-20
PCT/US2007/082164 WO2008133706A2 (en) 2006-10-20 2007-10-22 Fully human anti-vegf antibodies and methods of using

Publications (2)

Publication Number Publication Date
JP2010507594A true JP2010507594A (ja) 2010-03-11
JP2010507594A5 JP2010507594A5 (enExample) 2010-12-09

Family

ID=39926241

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009533598A Pending JP2010507594A (ja) 2006-10-20 2007-10-22 完全ヒト抗ｖｅｇｆ抗体および使用方法

Country Status (7)

Country Link
US (1) US20110076279A1 (enExample)
EP (1) EP2086583A4 (enExample)
JP (1) JP2010507594A (enExample)
CN (1) CN102006885A (enExample)
CA (1) CA2666974A1 (enExample)
MX (1) MX2009004027A (enExample)
WO (1) WO2008133706A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2014104406A1 (ja) * 2012-12-27 2017-01-19 学校法人慶應義塾 骨粗鬆症治療剤及び治療剤のスクリーニング方法
WO2017094733A1 (ja) * 2015-11-30 2017-06-08 日産化学工業株式会社 分子標的医薬に結合するｄｎａアプタマー及びそれを用いる分子標的医薬の検出方法

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7750124B2 (en) 2006-09-29 2010-07-06 Oncomed Pharmaceuticals, Inc. Anti-human DLL4 antibodies and compositions
CA2702637A1 (en) * 2007-10-22 2009-04-30 Schering Corporation Fully human anti-vegf antibodies and methods of using
KR101093717B1 (ko) * 2008-11-26 2011-12-19 한국생명공학연구원 Ｖｅｇｆ―특이적인 인간항체
WO2010124009A2 (en) * 2009-04-21 2010-10-28 Schering Corporation Fully human anti-vegf antibodies and methods of using
CN102459346B (zh) 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
CN102002104A (zh) * 2009-08-28 2011-04-06 江苏先声药物研究有限公司 一种抗vegf的单克隆抗体及含有该抗体的药物组合物
EP3485908B1 (en) 2009-10-16 2021-08-18 Mereo BioPharma 5, Inc. Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
CN102167740B (zh) * 2010-02-25 2014-06-04 上海百迈博制药有限公司 一种全人源抗vegf单克隆抗体、其制备方法及用途
US20120225081A1 (en) * 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
CN102757495A (zh) * 2011-04-26 2012-10-31 中国人民解放军第二军医大学 一种全人源抗vegf抗体、其制备方法及用途
CN102875676B (zh) * 2011-07-13 2014-11-05 无锡天演生物技术有限公司 全人源抗人vegf单抗分子及其应用
HRP20190044T1 (hr) 2011-09-23 2019-02-22 Oncomed Pharmaceuticals, Inc. Agensi koji vežu vegf/dll4 i njihove uporabe
AU2013337811A1 (en) 2012-10-31 2015-05-14 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
JP2016530244A (ja) * 2013-12-31 2016-09-29 ディベロップメント センター フォー バイオテクノロジーＤｅｖｅｌｏｐｍｅｎｔ Ｃｅｎｔｅｒ Ｆｏｒ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ 抗ｖｅｇｆ抗体及びその使用
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
MX382902B (es) 2014-10-31 2025-03-13 Oncomed Pharm Inc Inhibidor de la vía noth en combinación con un agente inmunoterapéutico para usarse en el tratamiento de cáncer.
WO2017053705A1 (en) 2015-09-23 2017-03-30 Oncomed Pharmaceuticals, Inc. Methods and compositions for treatment of cancer
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
JP6949106B2 (ja) * 2016-08-23 2021-10-13 メディミューン リミテッド 抗ｖｅｇｆ−ａ抗体ならびにそれらの使用
JP2021508471A (ja) 2017-12-29 2021-03-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ｖｅｇｆ抗体のｖｅｇｆ受容体遮断選択性を改善する方法
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
WO2020127864A1 (en) * 2018-12-21 2020-06-25 F. Hoffmann-La Roche Ag Method for improving inhibition of vegf-binding to vegf-r1 of an anti-vegf antibody
WO2021013064A1 (zh) * 2019-07-19 2021-01-28 神州细胞工程有限公司 一种人源化vegfr2抗体及其应用
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2023109904A1 (zh) * 2021-12-16 2023-06-22 石药集团中奇制药技术（石家庄）有限公司 多西他赛白蛋白组合物与vegf抑制剂或vegfr抑制剂的组合及用途
US20250236680A1 (en) * 2022-03-30 2025-07-24 Xi An Orimab Biotechnology Company Ltd. Anti-psma antibodies, variants, and uses thereof
CN115850470B (zh) * 2022-12-12 2023-07-07 三门峡市眼科医院 Vegf抗体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005054273A2 (en) * 2003-11-26 2005-06-16 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
US20060115477A1 (en) * 2002-12-20 2006-06-01 Unger Christine M Neuropilin-1 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2236634T3 (es) * 1997-04-07 2005-07-16 Genentech, Inc. Anticuerpos anti-vegf.
DK1354034T3 (da) * 2000-11-30 2008-03-25 Medarex Inc Transgene transchromosomale gnavere til fremstilling af humane antistoffer
US20050232921A1 (en) * 2001-04-13 2005-10-20 Rosen Craig A Vascular endothelial growth factor 2
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
SI1851315T1 (sl) * 2005-02-02 2014-06-30 University Of Massachusetts Humana protitelesa proti steklini in njihova uporaba
CA2702637A1 (en) * 2007-10-22 2009-04-30 Schering Corporation Fully human anti-vegf antibodies and methods of using

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060115477A1 (en) * 2002-12-20 2006-06-01 Unger Christine M Neuropilin-1 inhibitors
WO2005054273A2 (en) * 2003-11-26 2005-06-16 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6012051088; Ｂｉｏｃｈｅｍ．　Ｂｉｏｐｈｙｓ．　Ｒｅｓ．　Ｃｏｍｍｕｎ．，　３３３（２００５）　ｐ．３２８-３３５ *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2014104406A1 (ja) * 2012-12-27 2017-01-19 学校法人慶應義塾 骨粗鬆症治療剤及び治療剤のスクリーニング方法
WO2017094733A1 (ja) * 2015-11-30 2017-06-08 日産化学工業株式会社 分子標的医薬に結合するｄｎａアプタマー及びそれを用いる分子標的医薬の検出方法
US10640772B2 (en) 2015-11-30 2020-05-05 Nissan Chemical Industries, Ltd. DNA aptamers binding to molecular targeted agents and detection method of molecular targeted medicine using the same

Also Published As

Publication number Publication date
CN102006885A (zh) 2011-04-06
US20110076279A1 (en) 2011-03-31
EP2086583A4 (en) 2010-05-26
WO2008133706A2 (en) 2008-11-06
WO2008133706A8 (en) 2010-05-14
EP2086583A2 (en) 2009-08-12
WO2008133706A3 (en) 2009-02-19
CA2666974A1 (en) 2008-11-06
MX2009004027A (es) 2009-09-28

Similar Documents

Publication Publication Date Title
JP2010507594A (ja) 完全ヒト抗ｖｅｇｆ抗体および使用方法
JP6661734B2 (ja) 線維芽増殖因子受容体２に対するモノクローナル抗体
ES2435727T3 (es) Anticuerpo contra PDGFR-alfa para uso en el tratamiento de tumores
JP5769969B2 (ja) Ａｘｌ抗体
ES2527871T3 (es) Anticuerpos completamente humanos dirigidos contra el receptor del factor de crecimiento 1 similar a la insulina humana
CA2741127C (en) Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment
KR102360967B1 (ko) 신규 항-네트린-1 항체
JP2011505120A5 (enExample)
KR20100075559A (ko) 헤파린-결합 표피 성장 인자-유사 성장 인자 항원 결합 단백질
US20090246205A1 (en) Inhibition of macrophage-stimulating protein receptor (ron)
US20150110788A1 (en) Bispecific antibodies with an fgf2 binding domain
WO2017048699A2 (en) Highly potent monoclonal antibodies to angiogenic factors
ES2871598T3 (es) Anticuerpo novedoso contra EGFRvIII y composición que comprende el mismo
US20210238297A1 (en) Highly potent antibodies binding to death receptor 4 and death receptor 5
CN116940597A (zh) 多特异性抗体及其用途
TW201716439A (zh) Ｈｅｒ３抗體
US20150152193A1 (en) Axl antibodies
TW202543685A (zh) 抗體藥物偶聯物及其製備方法和用途
KR20250148463A (ko) 담도암의 치료를 위한 항-her2/항-4-1bb 이중 특이 항체
EA046745B1 (ru) Способ лечения рака активируемым антителом против pdl1
HK1260561A1 (en) Highly potent antibodies binding to death receptor 4 and death receptor 5
HK1260561B (en) Highly potent antibodies binding to death receptor 4 and death receptor 5
HK1185622B (zh) Axl抗体
HK1147275B (en) Axl antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101022

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101022

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121002

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130305